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PART A: LITERATURE REVIEW 
Part A: Literature review 
Background 
Globally, ST-segment elevation myocardial infarction (STEMI) is a serious complication of 
coronary heart disease, with an estimated annual incidence affecting seven million people 
and a major cause of death worldwide.(1) In the United States of America (USA), 
approximately 500,000 episodes of acute myocardial infarction (including non-STEMI and 
STEMI) occur each year; approximately 600 men and 200 women in every 100,000 population 
suffer from a myocardial infarction every year.(1-3) Nonetheless, the overall mortality rate has 
been decreasing in the USA: the 30-day mortality rate among patients with myocardial 
infarction in 2010 ranged only from 2.5 to 10%. Elsewhere, the World Health Organization 
(WHO) estimates that 17.5 million people died from some form of coronary heart disease 
(including infarction) in 2012, which represented 31% of all deaths globally. (4) However, most 
of these data are collected from high-income countries and substantially less is known about 
coronary heart disease in low- to middle-income countries, specifically those in Africa. 
Aim 
It was the aim of this critical review to provide an overview of the existing literature 
surrounding the definition, diagnosis, management and outcomes of STEMI and to interpret 
this within a South African, middle-income context. 
Objectives 
• To describe the definition and diagnosis of STEMI 
• To describe the management of STEMI in terms of percutaneous coronary intervention 
and thrombolysis 
• To describe the reported outcomes following STEMI 






Literature search strategy 
The University of Cape Town Health Sciences Library website was used to perform searches 
to obtain the original articles reviewed in this study. PubMed and Google Scholar were 
primarily used to perform searches using the following MESH terms in various combinations: 
cardiovascular disease, coronary disease, coronary artery disease, myocardial ischaemia/ 
ischaemia, unstable angina, myocardial infarction, non-ST-elevation myocardial infarction, 
ST-elevation myocardial infarction, treatment, outcome, diagnosis, South Africa, acute, and 
emergency. A snowball strategy was then used whereby publications cited in the articles 
included from the initial search that directly addressed the review aim were also accessed 
and assessed for inclusion in the review. 
Inclusion criteria: 
• Publication date: January 2000 – March 2017 
• Language: English, including studies translated and published 
Exclusion criteria: 
• Studies outside of the stipulated timeframe 
• Studies where the full text was not accessible 
• Studies that did not directly address the review objectives 
• Language other than English 
 
Quality criteria 
Titles and abstracts were initially screened for relevance to the review aim. Those deemed to 
have low relevance or poor external validity were excluded. High-quality evidence, including 
systematic reviews, were sought to address the aim and objectives. Although critical reviews 
do not typically require a formal assessment of quality, included studies were appraised 
against a checklist from the Oxford Centre for Evidence-Based Medicine 
(http://www.cebm.net/critical-appraisal/) to provide at least some indication of the strength 
of each study’s contribution. A representation in tabular form of appraised papers is not 
required for the MMed and was therefore omitted. Very little data were available that 
directly addressed some parts of the aim and objectives (particularly with regard to coronary 
heart disease and STEMI in low- and middle-income settings) and therefore criteria were 





Coronary artery disease (CAD): accounts for more than 30% of death in the West and presents 
acutely as acute coronary syndrome. Coronary artery disease is also known as coronary heart 
disease (CHD).(1-3,5,6)  
Acute coronary syndrome (ACS): a spectrum of clinical presentation ranging from unstable 
angina to non-ST-segment elevation myocardial infarction and ST-segment myocardial 
infarction. Acute coronary syndrome refers to ischaemic symptoms resulting from acute 
coronary occlusion. (1-3,5,6)  
Myocardial infarction: clinical evidence of acute myocardial ischaemia in the context of 
myocardial necrosis with rise and/or fall of cardiac troponins. Myocardial ischaemia is the 
initial step of the development of myocardial infarction and is due to oxygen supply and 
demand imbalance. The term ‘myocardial infarction’ should be used in the context of 
myocardial necrosis associated with the clinical presentation of myocardial ischaemia.(1-3,5,6)  
ST-elevation myocardial infarction (STEMI): a presentation of clinical symptoms consistent 
with an ACS combined with ST-segment elevation on electrocardiogram (ECG).(1-3,5,6)  
Non-ST-elevation myocardial infarction (NSTEMI): characterised by an elevation of serum 
troponin levels in the absence of ST-segment elevation. (1-3,5,6) 
Non-ST-elevation acute coronary syndrome (NSTE-ACS): refers to any ACS that does not show 
ST-segment elevation. It includes NSTEMI and unstable angina and is characterised by ST-
segment depression or transient ST-segment elevation which may become normal. (1-3,5,6) 
Unstable angina: characterised by typical ischaemic symptoms, with or without ECG 












Although initially characterised by a low prevalence of non-communicable disease, sub-
Saharan Africa has seen an increase of coronary heart disease over the last few decades.(4,7) 
The WHO has predicted that non-communicable diseases will exceed communicable or 
infectious diseases as the leading cause of death in Africa by 2030.(4) However, compared to 
other causes of heart disease, the burden of coronary heart disease remains low in African 
descendants.(7-14) Post-apartheid South Africa, with its emerging economy and urbanisation, 
has seen an increase in mortality and morbidity associated with coronary heart disease and 
its complications – such as myocardial infarction.(7-14) South African statistics indicate an 
annual mortality attributable to coronary heart disease in Indian and white populations as 
207 and 163 deaths per 100,000 population, respectively.(14) However, in the African 
population the rate was only 13 deaths per 100,000 population.(14) The prevalence of acute 
myocardial infarction in Africa is estimated to be between 0.1 to 4%.(15) However, an accurate 
prevalence of acute myocardial infarction in sub-Saharan Africa has not been well established 
despite growing recognition of the increasing burden of cardiovascular disease in low- and 
middle-income countries.(15) There is insufficient population-based data describing the 
prevalence of acute myocardial ischaemia in sub-Saharan Africa using common diagnostic 
criteria. The lack of surveillance data and registries as well as the lack of diagnostic and 
interventional capacities has made the estimation of the magnitude of coronary heart 
diseases in Africa challenging. (16,17) The paucity of epidemiological data as well as the absence 
of specific tests for coronary heart disease has also contributed to the failure to accurately 
determine the true prevalence of STEMI in Africa. (16,17) 
Most sources citing prevalence and incidence locally rely on estimated numbers. This is 
mainly due to a lack of consistent registry data. (16-19) As a result, the true burden of coronary 
heart disease is unknown. The ACCESS study conducted in 29 South African health facilities 
across all provinces from 2007-2008 was the first local study of its kind to establish registries 
and document the demographics and management strategies in patients admitted to 
hospital with a diagnosis of ACS. (20) Out of 642 patients enrolled in the study, 615 participants 
had a confirmed diagnosis of ACS: 41% had a diagnosis of STEMI at discharge versus 59% with 
NSTE-ACS (32% NSTEMI and 27% unstable angina). This study also revealed that the vast 
majority of South African patients with STEMI were managed at a facility without 
percutaneous coronary intervention (PCI) capabilities and by a non-cardiologist to boot – 
South Africa has only 62 cardiac catheterisation laboratories spread out between a few 
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tertiary public centres and selected private hospitals situated mainly in major urban centres. 
(21) What is interesting is that ACCESS was not a population representative sample. Study 
participants mostly had access to private health care, leaving the biggest cohort of South 
African patients with STEMI, namely, those from the public sector, largely excluded. (20) In a 
nutshell, this means that access to PCI capable facilities locally is likely more dreadful than 
what the study findings suggested. 
 
Broad definition of STEMI 
ACS is a broad term that refers to a cohort of clinical diseases resulting from acute myocardial 
ischaemia. (1-6) The term myocardial infarction refers to measurable evidence of myocardial 
necrosis (usually by means of a troponin rise), in the setting of a clinical presentation 
consistent with myocardial ischaemia.(1-6) It is an important concept to grasp when defining 
STEMI that not all ACS is associated with infarction and that not all infarction is associated 




Figure 1. A simplified representation of the spectrum of coronary heart disease. Boxes in 
black indicate an association with ischaemia and boxes in red indicate ischaemia that has 



















It is further important to note that not all myocardial infarction stems primarily from 
coronary heart disease. The cause of infarction may vary and currently acute myocardial 
infarction is classified into five different types (Box 1). (5,6,22,23) From an emergency centre (EC) 
perspective, we were mainly concerned with types 1 through 3, although the others may 
present at times. 
Box 1. Classification of acute myocardial infarction (5,6,22,23) 
Type 1 refers to spontaneous myocardial infarction. It is characterised by atherosclerotic 
plaque rupture, ulceration, erosion, or dissection with resulting intraluminal thrombus in 
one or more of the coronary arteries leading to decreased myocardial blood flow or distal 
platelet emboli with ensuing myocyte necrosis. 
Type 2 refers to myocardial infarction due to ischaemic imbalance. It is caused by 
conditions other than coronary artery diseases and leads to imbalances between 
myocardial oxygen supply and/or demand e.g., coronary endothelial dysfunction, coronary 
artery spasm, coronary embolism, tachy-/ brady-arrhythmias, anaemia, respiratory failure, 
hypotension, and hypertension with or without left ventricular hypertrophy. 
Type 3 is defined as myocardial infarction resulting in death before cardiac markers are 
available or collected. It is characterised by cardiac death with symptoms suggestive of 
myocardial ischaemia and presumed new ischaemic ECG changes or new left bundle 
branch block (LBBB), but death occurs before collection of blood samples, before rise of 
cardiac markers or cardiac markers were not obtained. 
Type 4a refers to myocardial infarction related to percutaneous coronary interventions 
(complex specific criteria). 
Type 4b is myocardial infarction related to stent thrombosis (complex specific criteria). 
Type 5 is defined as myocardial infarction observed in patients with a coronary artery 
bypass graft (complex specific criteria). 
 
A very specific acute myocardial infarction, STEMI, is characterised through clinical symptoms 
consistent with ACS in combination with specific ST-segment changes from baseline (bar a 
few exceptions) on the 12-lead ECG. (1-6,22,23) The reason STEMI has been identified separately 
from NSTEMI relates to the variation in treatment and outcomes between the two. ST-
elevation myocardial infarction is most often caused by a total occlusion of a coronary artery 
that necessitates an earlier, more acute approach, compared to NSTEMI. (2-6,22,23) Outcomes 
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tend to be worse if not addressed in a timely fashion. The diagnosis of STEMI is rarely delayed 
for cardiac enzymes, but rather is made based on the 12-lead ECG findings. Interpretation of 
the ECG is an essential skill in the emergency centre for this very reason. 
 
ST-elevation, cardiac anatomical regions and outcomes 
ST-elevation myocardial infarction has been the subject of many studies. One area of our 
study has been to define the anatomical areas associated with different coronary vessels 
affected and its downstream complications and outcomes. 
Inferior myocardial infarction accounts for more than half of all myocardial infarction 
presentations. It is characterised by ST-segment elevation in inferior leads (II, III and aVF) 
with reciprocal changes in leads I and aVL. It is caused by the occlusion of the right coronary 
artery distal to the right ventricle and has generally a more favourable prognosis than 
anterior myocardial infarction. Inferior myocardial infarction can be associated with 
concomitant right ventricular infarction and right precordial leads (V3R and V4R) are required 
to diagnose right ventricular infarction. Inferior myocardial infarction with right ventricular 
myocardial involvement is characterised by ST-segment elevation in inferior leads (II, III and 
aVF), in V1 and V4R. It is due to right coronary artery occlusion proximal to the right ventricle, 
represents 40% of all inferior myocardial infarction and is associated with a high mortality. (1-
6,22-25) 
Inferior STEMI can also be due to a posterior infarction. Acute myocardial infarction of the 
infero-basal portion of the heart is often caused by the occlusion of the right coronary artery 
as well as the left circumflex artery. The right coronary artery, through its posterior 
descending branches, perfuses the posterior wall of the heart. It is important to note that the 
left circumflex artery also supplies blood to the posterior wall. Acute posterior myocardial 
infarction occurs in 15-20% of STEMIs. It should be suspected in the presence of ST-
depression in leads V1 through V3 particularly if the terminal T-wave is positive (ST-elevation 
equivalent) and can be confirmed by obtaining leads V7 through V9 which shows ST-elevation 
>0.1 mv (1mm) in these leads (V7-V9). Therefore, tall R waves, ST-segment depression and 
upright T waves are characteristics of posterior wall injury. This type of infarction leads to 
worse outcomes due to an increasing area of myocardium at risk. The combination of 
posterior myocardial infarction with ST-elevation in either the inferior or anterior regions has 
been shown to be associated with a more extensive infarct. A 15-lead ECG is paramount in 
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the diagnosis of posterior myocardial infarct and increases its diagnostic sensitivity to nearly 
90%. (24-25)   
Septal, anterior and lateral myocardial infarctions are due to an occlusion of the left anterior 
descending artery. The ECG diagnostic features of lateral myocardial infarction include ST-
segment elevation in leads V5, V6, I and aVL, whilst septal myocardial infarction is 
characterised by ST-segment elevation in leads V1 and V2. (1-6,22-23)  ST-elevation in leads V3 
and V4 are features of an anterior myocardial infarction. Anterior myocardial infarction has 
been shown to carry the worst prognosis of all infarctions mainly due to the larger size of the 
infarct. Other presentations of anterior ischaemia include left mainstem coronary artery 
occlusion, De Winter and Wellens syndrome. (1-6,22-26) 
ST-elevation in leads aVR and/ or V1 combined with ST-depression of more than 0.1 mv 
(1mm) in the inferior and lateral leads are suggestive of ischaemia caused by multi-vessel or 
left mainstem coronary artery obstruction. The ratio of ST-segment elevation (aVR/ V1) is an 
important clue in differentiating a left mainstem coronary artery occlusion from a left 
anterior descending artery occlusion. Although an acute left mainstem coronary artery 
occlusion is rare, it is a dangerous condition that needs urgent attention and management as 
the left mainstem coronary artery perfuses a large part of the anterior wall of the heart. 
Occlusion here may lead to life-threatening dysrhythmia and cardiogenic shock. However, 
the presence of collateral circulation may be the reason it is rarely observed. ST-elevation in 
the aVR lead is an excellent predictor of left mainstem coronary artery occlusion with nearly 
an 80% sensitivity and specificity. Patients with left mainstem coronary artery occlusion are 
characterised by a greater amplitude of ST-elevation in aVR than V1. Moreover, aVR 
abnormalities are associated with increased mortality and predict mortality with around a 
75% specificity and sensitivity. (22-26) 
The De Winter’s wave is a very specific presentation of anterior myocardial infarction. It is 
also referred to as an anterior ST-elevation myocardial infarction equivalent. Its diagnostic 
features include ST-segment depression coupled with a peaked T, tall, symmetrical, narrow 
wave in the precordial leads. However, ST-elevation (0.5-1mm) in the aVR lead may also be 
observed. De Winter’s wave presentation accounts for 2% of all left anterior descending 
artery occlusions and is sometimes considered as a subtype of the hyper-acute T-wave. It is 
suggestive of an acute high grade left mainstem coronary artery occlusion as opposed to the 
sub-acute occlusion of Wellens syndrome (see below) and characterises an unstable lesion 




Wellens’ syndrome is characterised by deeply inverted or biphasic T waves in V2-V3 and is 
suggestive of critical stenosis of the left anterior descending artery. It is diagnosed in the 
context of resolved angina-type chest pain associated with characteristic ECG changes and a 
normal to minimal leak of cardiac biomarkers. It carries a poor prognosis where treated 
medically and usually requires catheter-based intervention. Patients with a Wellens pattern 
are at an increased risk for left ventricular dysfunction. Performing a cardiac stress test when 
present is inappropriate due to a greater risk of STEMI. (27-30) 
The diagnosis of acute myocardial infarction in the presence of left bundle branch block is 
difficult to establish but clinical algorithms have been designed to address the issue. New left 
bundle branch block alone is no longer an indicator for activating the cardiac catheterisation 
laboratory. However, percutaneous coronary intervention (PCI) for left bundle branch block 
should be considered in circumstances such as when an unstable patient presents with 
hypotension, pulmonary oedema or electrical instability, or the Sgarbossa and Smith-
modified Sgarbossa criteria are satisfied. The original Sgarbossa criteria had a sensitivity of 
52% for identifying STEMI in the presence of left bundle branch block. (31-33) Smith et al. 
replaced the third Sgarbossa criteria with the discordant (ST/ T-wave) ratio of more than 25%, 
which increased the sensitivity of the criteria to 91%.(34) 
It is important to note that other conditions may present with ST-segment elevation and 
these need immediate recognition to avoid unnecessary treatment. These conditions are 
referred to as STEMI mimics and include left ventricular hypertrophy with secondary 
repolarisation pattern, Prinzmetal’s angina, aneurysm, benign early repolarisation, acute 
pericarditis, pulmonary embolism and acute aortic dissection. Treating some of these 
conditions with thrombolytic therapy may result in serious complications and increase 
morbidity and mortality. (35) 
 
Diagnosis of STEMI 
Patient history, physical examination, 12-lead ECG and cardiac biomarkers are key 
components in the diagnosis and management of STEMI.  
History and physical examination 
The chief complaint of ACS is crushing central chest pain. Prolonged pain is documented in 
80% of patients while new or crescendo angina is observed in 20% of patients. The typical 
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clinical presentation of ACS is retrosternal pressure or heaviness that radiates to the left arm, 
neck or jaw. (1-6,22,23) 
However, atypical presentations are not uncommon and may include epigastric pain, 
indigestion, stabbing chest pain with some pleuritic features or increasing breathlessness. 
Atypical symptoms are more common in older patients (older than 75 years), in women and 
in patients with diabetes, chronic renal failure or dementia. (1-6,22,23) 
Physical examination  
The physical examination is chiefly aimed at ruling out non-cardiac causes of chest pain such 
as pulmonary embolism, aortic dissection, pericarditis, valvular heart disease and pulmonary 
diseases e.g., pneumothorax, pneumonia or pleural effusion. 
The 12-lead ECG 
Ideally, the 12-lead ECG should be performed and interpreted by an experienced provider 
within ten minutes from first medical contact. (1)  
ST-segment elevation in acute myocardial infarction is measured at the J point (junction of 
the ST segment and QRS complex) in two contiguous leads. Measurements should be greater 
than 0.25 mv (2.5mm) in men younger than 40 years, greater than 0.2 mv (2mm) in men older 
than 40 years, greater than 0.15 mv (1.5mm) in women in leads V2-V3, and/ or greater than 
0.1 mv (1mm) in other contiguous chest or limb leads (in the absence of left ventricular 
hypertrophy or left bundle branch block) to be diagnostic. (1-6,22,23) 
The ECG is an important diagnostic tool for the initial triage of undifferentiated chest pain. It 
is very specific for STEMI but not very sensitive meaning that is very good to make the 
diagnosis of myocardial infarction but not so good at ruling it out. The sensitivity and 
specificity of a single ECG for acute myocardial infarction is estimated to be around 60% and 
90%, respectively. (17) The predictive value of the ECG is very variable and depends on the pre-
test probability of coronary disease in the patient. Moreover, the number and magnitude of 
ECG abnormalities also influence its specificity and sensitivity. (1-6,22,23) Therefore, non-
diagnostic and even normal ECGs do not exclude the diagnosis of acute myocardial infarction. 
Roughly 20% of patients diagnosed with acute myocardial infarction had an initial non-
diagnostic ECG. (1) Serial ECGs should be obtained in situations where the initial ECG is non-
diagnostic but the clinical presentation is highly in favour of the diagnosis of ACS. It is also 
important to note that in the setting of on-going or recurrent chest pain, serial ECGs have 
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proven to decrease false negatives and false positives and therefore help to prevent 
unnecessary treatment or under-treatment. (1-6,22,23) 
Although coronary angiography is the reference standard for the diagnosis of infarction, ECG 
remains the standard diagnostic tool that enables the identification of the presence, 
approximate location and extent of acute myocardial ischaemia and injury. Measurement of 
the absolute magnitude of ST-segment elevation or the width of QRS complexes is key in the 
ECG assessment of STEMI. ( 1-6,22,23)   
As described earlier, different anatomical cardiac regions are associated with different 
outcomes and in some cases, slightly different treatment strategies. Table 1 describes the 
various STEMI regions and their ECG findings.  
 
Table 1. Various STEMI regions, the main leads affected and their ECG findings 
Location Leads affected ST segment 
Anterior wall MI 
 
V1 through V4 
II, III, aVF 
Elevation 
Depression 
Lateral MI I, aVL, V5 and V6 Elevation 
Inferior wall MI II, III and aVF 
I, aVL, V5 and V6 
Elevation 
Depression 
Right ventricular MI V4R 
II, III, aVF 
Elevation 
Elevation 
Posterior wall MI V8 and V9 Elevation 
 V1 through V3 Depression 
 
A good strategy after obtaining a 12-lead ECG is to rapidly classify patients into one of four 
categories as follows: those with evidence of ST-segment elevation on initial ECG; those 
without ST-segment elevation but who are at high risk based on ECG findings, haemodynamic 
instability, or history; those who have no objective evidence of ACS but have symptoms that 
warrant evaluation; and those who have an obvious non-cardiac cause for their symptoms. 




High sensitivity troponins improve the rapid rule out of myocardial infarction and 
confirmation of NSTEMI. (1-6,22,23) The diagnosis of STEMI is made in the presence of specific 
clinical settings with appropriate ECG changes and is not based on troponins. However, 
cardiac biomarkers are required to differentiate NSTEMI from unstable angina in NSTE-ACS). 
(1-6,22-24) As such, a discussion of cardiac biomarkers falls beyond the scope of this review. 
 
The acute management of STEMI 
The optimal care of STEMI patients comprises provision of the fastest, safest and most 
effective method of reperfusion available within the boundaries of the resources available to 
a specific setting. The cornerstone of management of STEMI remains to be early reperfusion 
of the ischaemic myocytes. Treatment is aimed at establishing early patency of an infarcted 
area that is critical in determining short- and long-term outcomes. Two modalities for 
reperfusion therapy have been described and include percutaneous coronary intervention 
(mechanical revascularisation) and thrombolysis (pharmacological revascularisation). (1-6)  
Percutaneous coronary interventions 
Myocardial revascularisation is the mainstay for the management of STEMI and is indicated 
when the expected benefits such as survival or health outcomes (symptoms, functional status 
and/ or quality of life) outweigh the expected risks. Therefore, the main goal of coronary 
angiography with revascularisation includes relief of symptoms and improvement of short- 
and long-term outcomes. (1-6,22,23) 
Primary PCI is defined as PCI provided to patients without previous or concomitant 
administration of thrombolytic therapy. Patients with isolated proximal left anterior 
descending artery disease, multi-vessel disease and left mainstem coronary artery occlusion 
usually require primary PCI as the management of choice. Primary PCI should ideally be 
offered to STEMI patients at a PCI-capable facility within 60 minutes of presentation to the 
EC.(1-6,22,23) However, where delays are anticipated to be more than 120 minutes from the 
time of presentation, thrombolysis should be administered.(1-6,22,23) Percutaneous coronary 
intervention and thrombolysis are equivalent in efficacy for patients presenting within three 
hours of onset of ischaemic symptoms.(5,6,22,23) Immediate transfer to a PCI-capable hospital 
for primary PCI is the recommended triage strategy for patients with STEMI who present at 
a non-PCI capable hospital with a first medical contact to device time goal of 120 minutes or 
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less.(1-6,22,23) The major benefits of reperfusion therapy as related to survival are time-
dependent. That said, the loss of efficacy caused by a delay tends to be more pronounced 
with thrombolysis than with PCI. (1-6,22,23) 
Delayed percutaneous coronary intervention 
The persistence of STEMI despite thrombolysis (i.e., failed thrombolysis) and/ or persistent 
ischaemic chest pain post-thrombolytic administration, warrant a rapid transfer to a PCI 
centre for rescue PCI. The administration of a second dose of thrombolysis has not shown 
any benefit, but increases the risk of mortality and morbidity.(22-23) Other patients that may 
benefit from delayed PCI include those with successful reperfusion, or post-thrombolysis 
patients who are referred within 24 hours to a cardiac catheterisation laboratory for 
angiography and revascularisation.(22-23) It is important to note that similar benefits were 
observed in patients who presented between 12 and 24 hours from symptom onset and in 
some cases up to 60 hours from symptom onset.(22-23) There are no proven benefits of 
referring patients without on-going chest pain or inducible ischaemia who present beyond 
72 hours for delayed PCI.(5,6,22,23) 
Several randomised controlled trials and meta-analyses have shown benefit when 
transferring patients with STEMI from a non-PCI hospital to a PCI-capable facility for primary 
PCI. These benefits include effective restoration of vessel patency, reduced re-occlusion, 
improved left ventricular function, better clinical outcomes as well as reduced mortality. In 
the Danish Multicentre Randomised Study on thrombolytic therapy versus Acute coronary 
angioplasty in Acute Myocardial (DANAMI-2) study, timely transfer of patients with STEMI 
from non- PCI hospital to a PCI-capable facility for primary PCI resulted in the improvement 
of outcomes such as reduction in re-infarction rate. The average first door-to-device time 
was around 110 minutes. (36,37) The Acute Coronary Treatment and Interventions Registry 
Outcomes Network (ACTION) study looked at 14,821 patients and found that the median 
door-in/ door-out times were 68 minutes; only 11% of patients achieved a door-in/ door-out 
time of less than 30 minutes.(38) 
On the flipside, prolonged transfer times to a PCI-capable centre were associated with worse 
prognosis. The National Registry of Myocardial Infarction (NRMI)-2, -3, -4, -5 showed that 
delays during transfer of patients with STEMI for primary PCI exceeding 120 minutes from 
first medical contact were associated with negation of the survival advantage of PCI over 
thrombolysis. In this study, delays beyond 120 minutes occurred in almost 50% of the 
patients with STEMI recruited in the analysis.(39) McNamara RL and colleagues looked at the 
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management of 29,222 patients with STEMI in the US National Registry of Myocardial 
Infarction databases 3 and 4 and concluded that prolonged door to balloon times resulted in 
higher mortality ranging from 3% mortality for times less than 90 minutes to 7.4% mortality 
for times more than 150 minutes.(40) The Australia registry data for STEMI revealed that only 
36.5% of cases achieved a door to device time of less than 90 minutes. The median hospital 
door to angioplasty door and angioplasty door to angioplasty device time was 102 minutes. 
(41-42)   
As described, even high-income countries such as the USA, Australia and those within the 
European Union failed to achieve the evidence-based goals set for PCI. The provision of 
primary PCI within an evidence-based timeframe is challenging and difficult to achieve and 
varies worldwide. Ideally, a rapid assessment of patients with STEMI at a non-PCI capable 
facility should include time from onset of symptoms, risk of complications related to STEMI, 
risk of bleeding with thrombolysis, the presence of shock or severe heart failure and time 
required for transportation of the STEMI patients to a PCI-capable facility.(22-23) Although PCI 
remains the treatment of choice for STEMI and should be offered to all patients with STEMI 
if it can be performed effectively with a door-to-balloon time of less than 90 minutes by a 
skilled provider at a skilled PCI centre, this is simply not achievable in much of sub-Saharan 
Africa.(16,21)  
Thrombolytic therapy 
The provision of thrombolytic therapy has been shown to improve survival in patients 
presenting with STEMI and is also more widely available compared to PCI. It is considered an 
appropriate alternative reperfusion therapy for patients presenting with STEMI to non-PCI 
capable facilities where delay to a PCI capable facility is anticipated to be more than 120 
minutes, or if a PCI capable facility is simply not available. The decision to administer a 
thrombolytic agent to a patient with STEMI requires consideration of important factors such 
as location of the myocardial infarction, patient age, time of symptom onset to time of arrival 
at EC, time required to complete transfer to and performing of primary PCI (where available), 
and the capability of the primary PCI cardiologist and hospital.(1-6,22,23) Randomised controlled 
trials on thrombolytic therapy have demonstrated the benefits of early initiation of 
thrombolytic therapy after onset of STEMI. It has also been shown that myocardial infarction 
can be aborted completely and mortality significantly reduced if thrombolysis is provided 
within the first two hours, and particularly within the first hour. (1-6,22,23) Thrombolytic therapy 
has also shown benefit where PCI has been delayed for other, varied reasons.(1) 
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The maximum benefit of thrombolysis is seen when administered within 30 minutes of arrival 
at the EC (or first medical contact).(36,43-45) It is not appropriate in STEMI patients with contra-
indications to the thrombolytic agent or for those who are in cardiogenic shock. In these 
circumstances, PCI is considered superior to thrombolytic therapy as it also improves survival 
rates and enhances other important outcomes. Unfortunately, as already stated, PCI is not 
widely available. (1-6,22,23) 
In South Africa, a number of studies have considered the presentation of STEMI to public 
hospitals. Chetty et al. documented the incidence and management of patients with STEMI 
attending a public district hospital in KwaZulu-Natal, South Africa. (15) Out of 55 patients that 
presented with STEMI, 78% received thrombolysis, whilst 7% had contra-indications and 13% 
presented outside the effective thrombolysis window and did not receive thrombolysis. The 
investigators did not expand on how the non-thrombolysed cohort was subsequently 
managed. The study site achieved a mean door-to-needle time of 43 minutes. (15) Meel et al. 
considered similar objectives in their study conducted at a public tertiary hospital in Gauteng, 
South Africa. (46) Although the hospital did have a cardiology service, primary PCI was not 
available at the time. Out of 100 consecutive patients that presented with STEMI without a 
contra-indication to thrombolysis, only 37% received thrombolysis. Significant delays in 
presentation and transfer between healthcare facilities were mainly responsible for the poor 
results. Transfer from primary care and private facilities to the tertiary hospital took a median 
of eight hours. In-hospital delays contributed to a lesser extent, but it is worth mentioning as 
these are potentially modifiable variables. Delays here were mainly due to inappropriate 
triage, long queues to open folders, understaffed and overburdened ECs, and ECG machines 
that were not in working order. The study reported a median door-to-needle time of 63 
minutes. (46) Maharaj et al. documented the course of 238 STEMI patients that presented to 
three public hospitals in Cape Town, South Africa.(38) Of these patients, 74% were 
thrombolysed whilst 5% had contra-indications and 21% presented outside the effective 
thrombolysis window and did not receive thrombolysis. Delays here were mainly due to 
junior doctors seeking confirmation from a senior doctor before commencing thrombolysis, 
interpretation of the ECG, atypical presentations, clinical issues requiring priority, patients 
presenting during staff hand-over, delays in investigations and absence of thrombolytic 
agents in the EC. The study reported a median door-to-needle time of 54 minutes. (38) What 
these studies tell us is that although thrombolysis can be considered an appropriate 
alternative to PCI, in settings where PCI is not available, systems do not support early and 
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appropriate thrombolysis either. This is likely due to the reasons provided in the Meel and 
Maharaj studies. (38,46) 
Thrombolysis and routine transfer for angiography: 
The practice of transfer of patients with STEMI for routine early coronary angiography after 
initial thrombolytic therapy is growing. This new approach referred to as ‘early invasive 
strategy’ is believed to have the advantage of being initiated at a non-PCI capable facility, 
providing additional time for the facility to arrange non-emergency PCI. (47) It supports early 
transfer after administration of thrombolytic therapy even in patients without high-risk 
features. Studies promoting this practice have demonstrated improvements and benefits in 
clinical outcomes such as lower two-year mortality rates and lower risks of re-infarction. (47-
52) 
The TRANSFER- AMI TRIAL (The Trial of Routine Angioplasty and STENTING after thrombolysis 
to Enhancing Reperfusion in Acute Myocardial) evaluated the transfer for coronary 
angiography and revascularisation among high risk patients (n=1059) and demonstrated a 
reduction in the combined primary endpoint of death, recurrent MI, recurrent ischaemia, 
new or worsening heart failure or shock at 30 days.(47) In the GRACIA study, early 
catheterisation within 6-24 hours after successful thrombolysis was associated with 
significant reduction in mortality, re-infarction or ischaemia-driven revascularisation at two 
years.(49) The CARESS- AMI trial, a randomised multicentre trial of 600 subjects, compared the 
outcomes of immediate transfer for PCI following thrombolytic therapy in high risk patients 
to standard care and rescue PCI and demonstrated a benefit of the former in all causes of 
death, re-infarction rate and refractory ischaemia.(50) And finally, the NORDISTEMI 
(Norwegian Study on District Treatment of ST-elevation Myocardial infarction) trial 
investigated the effect of immediate routine transfer for catheterisation versus ischaemia-
guided management after thrombolysis of STEMI patients in areas with very long distances 
and showed a reduction in the incidence of death, recurrent MI or stroke in the immediate 
transfer group.(52) 
As stated, although PCI remains the revascularisation treatment of choice for the 
management of STEMI in high-income countries it must be performed in less than 120 
minutes from onset of chest pain or first medical contact by a skilled provider and at a skilled 
PCI centre to be effective. Early invasive strategy offers an evidence-based approach to 
achieving PCI that is unavoidably delayed, by starting with early thrombolysis. It is unclear, 
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however, what benefits this strategy holds for low- and middle-income countries where PCI 
is less available. (21) 
 
Assessment of reperfusion therapy efficacy 
In high-income countries, the assessment of thrombolytic therapy efficacy is based on 
various markers of perfusion. This includes the Thrombolysis in Myocardial Infarction trial 
(TIMI) flow grade classification, TIMI frame count (TMC), TIMI Myocardial Perfusion grade 
(TMP) and clinical variables such as relief of ischaemic symptoms, the presence of reperfusion 
arrhythmia and resolution of ST-segment elevation. (53,545) Several trials have demonstrated 
that complete or near complete ST-segment resolution at 90 minutes after thrombolysis is a 
marker of good prognosis. In contrast, the absence of improvement in ST- segment resolution 
is associated with worse prognosis. (53,54)                                                                                                                                          
The Hirudin for Improvement of Thrombolysis (HIT)- 4 trial demonstrated the association 
between the resolution of ST-segment elevation in patients thrombolysed for STEMI and the 
detection of early infarction vessel patency.(55) Cooper et al. also established the association 
between ST-segment amplitude and patency of the infarcted vessel after administration of 
thrombolysis.(56) Purcell et al. went one step further and found that changes in ST-segment 
elevation 60 minutes after thrombolysis initiation could predict clinical outcomes as 
accurately as later ECG changes.(57) The International Joint Efficacy Comparison of 
Thrombolytic Trial (INJECT) then showed that the extent of early ST- segment elevation 
resolution was a strong predictor of outcomes in patients with STEMI and a sensitive measure 
for comparison between thrombolytic agents.(58) 
The relatively sudden and complete relief of chest pain, combined with greater than 70% ST-
segment elevation (in leads with the greatest elevation on presentation) is highly suggestive 
of restoration of normal blood flow and may be equivalent to TIMI 3 classification. The 
combination of 50% resolution of ST-segment elevation with the absence of reperfusion 
arrhythmia predicts TIMI flow <3 in the infarcted artery with a sensitivity of 81%, specificity 
88%, positive predictive value 87% and negative predictive value of 83%. The lack of 
resolution of ST-segment elevation by at least 50% in the worst leads at 90 minutes prompts 
the need for an immediate coronary angiography and rescue PCI. (55) Therefore, successful 
reperfusion after thrombolysis is characterised by a significant improvement in ischaemic 
symptoms, resolution of ST-segment elevation on ECG as well as haemodynamic stability and 
the absence of heart failure.(55-61) 
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The evidence of unsuccessful reperfusion or failed primary reperfusion is clinically 
characterised by persistent or worsening chest pain associated with other symptoms such as 
dyspnoea and diaphoresis as well as persistent or worsening ST-segment elevation, and /or 
haemodynamic instability or heart failure. Failure of the primary reperfusion approach 
(thrombolysis) warrants emergency or immediate angiography with intention to perform 
rescue PCI. (56-58,62) 
 
Prognosis and outcomes 
Although thrombolytic therapy is easy to administer and widely available, it provides early 
reperfusion in only 80% of patients. (1) Sometimes, contra-indications of the thrombolytic 
agent hinder its administration to some patients presenting with STEMI. Myocardial 
revascularisation with PCI results in a higher reperfusion rate (approximately 90%) and has 
fewer contra-indications than thrombolysis. (63,64) Randomised controlled trials performed in 
high-volume academic centres comparing thrombolytic therapy with PCI for acute 
myocardial infarction demonstrated a 30% reduction in mortality and re-infarction rates, and 
a significant reduction in cerebrovascular accidents where PCI was employed. Although more 
forgiving than thrombolysis, primary PCI should be performed within 60-90 minutes of arrival 
to the hospital to achieve these figures. (63,64) 
Anneke et al. looked at 22 randomised controlled trials that evaluated the efficacy and safety 
of primary PCI versus thrombolysis and found that 446 patients with STEMI (6.6%) died within 
30 days after randomisation. (65) Patients randomised to primary PCI had lower mortality than 
those randomised to thrombolysis (5.3% versus 7.9%, adjusted odds ratio 0.63, 95% 
confidence interval 0.42-0.84, p=0.001). However, the absolute risk reduction was strongly 
related to estimated risk at baseline; the numbers needed to treat to prevent a death by 
primary PCI versus thrombolysis was 516 in the lowest quartile of estimated risk compared 
with only 17 in the highest quartile. Primary PCI was consistently associated with a strong 
relative reduction in 30-day mortality, irrespective of patient baseline risk. The investigators 
resultantly recommended that primary PCI should be considered as the first-choice 
reperfusion strategy whenever feasible. Where access to PCI is estimated to be more than 
two hours, the administration of thrombolysis remains a legitimate alternative option in low-
risk patients where primary PCI would lead to only a small absolute risk reduction. (65) 
Survivors of a first-time STEMI face an increased risk of further major cardiovascular events 
such as death, recurrent infarction, heart failure, arrhythmias, angina, and stroke. 
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Complications occurring after myocardial infarction are attributed to structural and electrical 
changes in the heart and depend on the extent of the myocardial damage. (63,65) There are 
early and late complications but only the former is considered in our study. Early 
complications include mortality, cardiogenic shock, severe heart failure, pericarditis, 
thromboembolic and bleeding complications, acute kidney injury, hyperglycaemia, recurrent 
ischaemia/ infarction, no-reflow phenomenon, right ventricular infarction, mechanical 
complications such as mitral regurgitation, ventricular septal rupture, left ventricle free-wall 
rupture, left ventricle aneurysm and electrical complications such as tachy-dysrhythmias or 
brady-dysrhythmias. (63,65) 
Electrical                                                                                                                                                                                                                                                     
Dysrhythmias and conduction abnormalities occur in more than 90% of STEMI patients and 
can result in death within the first three days. Atrial fibrillation and atrial flutter have been 
found in about 10% of patients. Ventricular dysrhythmias such as ventricular fibrillation and 
ventricular tachycardia are also common. (63,65) 
Structural complications 
Structural complications post-myocardial infarction include papillary muscle rupture, 
ventricular aneurysm, ventricular septal rupture and ventricular free-wall rupture. Free-wall 
rupture is almost always fatal. (63,65) 
Cardiogenic shock 
Cardiogenic shock occurs in almost 7% of patients with STEMI and has a mortality rate of 
roughly 80-90% if not treated. Primary PCI or coronary artery bypass grafting are the 
treatments of choice for STEMI complicated by cardiogenic shock with early intervention 
having a significant effect on mortality. The 30-day mortality rate is nearly 50% when 
cardiogenic shock is treated with an early catheter-based mode of revascularisation. (1-
6,22,23,63,65) 
 
Summary of critical review 
The selection of an appropriate method of myocardial revascularisation strategy requires 
consideration of information such as location of the myocardial infarction, patient age, the 
duration of STEMI from the onset of ischaemic symptoms, time required to complete transfer 
to a PCI facility and safely perform primary PCI, and the capability of the primary PCI 
cardiologist and health facility. Primary PCI is an effective treatment for STEMI if it is 
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performed within less than 90 minutes from onset of symptoms. It enhances early 
reperfusion in approximately 90% of patients who present with STEMI and has been 
associated with a 30% reduction in mortality and re-infarction rates as well as a significant 
reduction in recurrences. The main difficulty is that PCI is not widely available and requires 
special skills and a specialised facility. It is unfortunate to note that in low- and middle-income 
countries, many patients with STEMI will present to non-PCI capable facilities and therefore 
cannot be offered PCI. It has also been shown that many countries (including in high- and 
middle-income countries) struggle to meet the time-frames for effective PCI. Thrombolysis, 
despite being less effective than PCI, remains a treatment option for patients who present 
with STEMI where PCI is not available, or a delay in transfer to a PCI centre is expected. In the 
absence of PCI, the administration of thrombolytic agents is an effective alternative means 
of myocardial revascularisation and the treatment of choice in low- and middle-income 
countries as it is more readily available. Despite the risk of bleeding, reperfusion with 
thrombolysis results in an 80% success rate. However, lack of resources to provide PCI does 
not necessarily mean that resources exist to provide timely thrombolysis. Studies performed 
in South Africa have highlighted long delays in care and other challenges in providing 
thrombolysis for STEMI. (15,38,46) None of these studies specifically documented the 
contribution of rescue PCI. 
 
Identification of gaps or needs for further research 
There is a need for research within South Africa to consider the outcomes of patients with 
STEMI who were thrombolysed at a non-PCI capable facility in relation to the ECG changes 
associated with different coronary injury regions involved. A better understanding of the 
patients thrombolysed for STEMI that require transfer from a non-PCI capable facility may 
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There is insufficient data to describe ST-elevation myocardial infarction (STEMI) in sub-
Saharan African settings using common diagnostic criteria. This study describes the outcomes 
at discharge (survival, death or transferred) of patients thrombolysed for STEMI at a public 
hospital without primary percutaneous coronary intervention capability as well as associated 
ECG changes. 
Materials and methods 
A retrospective, cross- sectional study was conducted at an urban, public emergency centre 
in Cape Town, South Africa that did not have direct access to percutaneous coronary 
intervention for STEMI. Descriptive statistics for age, length of stay and the various timings 
surrounding thrombolysis were presented using proportions, mean and standard deviation. 
Assumptions were tested using the X2-test or Fishers Exact test. A p-value less than 0.05 was 
considered significant. 
Results  
The study enrolled 104 patients of which 25 were excluded for insufficient data and two for 
thrombolysis of an incorrect STEMI diagnosis. Of the remaining patients, 56 (64%) survived 
to discharge, 26 (30%) required transfer and five (6%) died. There was no difference between 
regions affected and patient outcome (p=0.31). Resolution of ST-segments was seen in 48 
(86%) survivors. It was not seen in 21 (81%) who were transferred and in none that died. The 
difference between resolution of ST-segments between survivors versus those transferred or 
dead was highly significant (p<0.001). 
Conclusion 
This study described a higher than expected thrombolysis failure rate as well as a higher than 
expected association of poor outcome with inferior STEMI. It highlights the need for 
improved health care records to improve health research in low-resourced settings. The 
creation of a STEMI registry could contribute to research but will need funding. The use of 
clinical messaging apps to gain senior ECG interpretation may provide an additional layer 











Sub-Saharan Africa has been characterised by an increase in coronary heart disease over the 
last few decades. (1-2) The World Health Organization has predicted that non-communicable 
diseases will exceed communicable or infectious diseases as the leading cause of death in 
Africa by 2030.(1) Compared to other causes of heart disease, the burden of coronary heart 
disease remains low in African descendants compared to Caucasian descendants.(2-9)  
The prevalence of acute myocardial infarction in Africa is currently estimated to be between 
0.1 to 4%.(10) But an accurate prevalence of acute myocardial infarction in sub-Saharan Africa 
has not been well established despite growing recognition of an increasing burden of 
cardiovascular disease in low- and middle-income countries.(11-13) There is insufficient 
population-based data that describes the prevalence of acute myocardial ischaemia in sub-
Saharan Africa using common diagnostic criteria. The lack of surveillance data and registries 
as well as the lack of diagnostic and interventional capacities has made the estimation of the 
magnitude of coronary heart diseases in Africa challenging. The paucity of epidemiological 
data as well as the absence of specific tests for coronary heart disease has also contributed 
to the failure to accurately determine the true prevalence of ST-elevation myocardial 
infarction (STEMI) in Africa. (11-13) 
There has been an increase in mortality and morbidity rates associated with coronary heart 
disease and its complications – such as myocardial infarction – in post-apartheid South Africa 
with its emerging economy and increased urbanisation.(2-9) The ACCESS study conducted in 
29 South African health facilities across all provinces from 2007-2008 was the first local study 
to establish registries and document the demographics and management strategies in 
patients admitted to hospital with a diagnosis of acute coronary syndrome (ACS).(14) Out of 
642 patients enrolled in the study, 615 participants had a confirmed diagnosis of ACS: 41% 
had a diagnosis of STEMI at discharge versus 59% with non-ST-elevation ACS (NSTE-ACS) (32% 
non-ST-elevation MI and 27% unstable angina). This study also revealed that most South 
Africans presenting with STEMI were managed at a facility without percutaneous coronary 
intervention (PCI) capabilities and by a non-cardiologist – South Africa has only 55 cardiac 
catheterisation laboratories for a population of 56 million, spread out between a few tertiary 
public centres and selected private hospitals, mostly situated in major urban centres. (9,14) 
What is important to note is that ACCESS was not a population representative sample. Study 
participants mostly had access to private health care, leaving the biggest cohort of South 
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African patients with STEMI, namely, the 68% without access to private health care from the 
public sector, largely excluded. (15) In a nutshell, this means that access to PCI capable facilities 
is likely to be worse than what the ACCESS study findings suggested. 
It was the aim of this research to describe the outcomes at discharge from hospital, of 
patients thrombolysed for STEMI; and the ECG changes (e.g. STEMI regions and STEMI 
resolution) associated with this outcome, at a public hospital without PCI capability in Cape 
Town. 
 
Materials and methods 
This cross-sectional, retrospective study was conducted at Victoria Hospital, Cape Town. 
Victoria Hospital is a large, secondary-level hospital that provides medical and surgical 
services but has no PCI suite or cardiologist on site. The emergency centre (EC) has two 
resuscitation beds, eight beds for other EC patients (including three monitored beds) with a 
further 16 observation beds in an adjacent ward. Daily, the EC manages approximately 132 
patients of which around 15 present with chest pain. On average, five patients are admitted 
to medicine daily with a diagnosis of ACS and approximately two to five STEMIs are 
thrombolysed per week in the EC. Streptokinase is the preferred agent for all patients 
without contra-indications to the drug. Alteplase is only used in instances where 
Streptokinase is contra-indicated. Victoria Hospital is approximately ten kilometres away 
from the nearest PCI capable centre at Groote Schuur Hospital, a 20 to 40-minute trip 
depending on traffic. (16) 
We included all patients aged 18 years or older who presented with STEMI as defined by 
the clinical and ECG criteria described by the American College of Cardiology/ American 
Heart Association and were received in the EC between July 2014 and June 2015.(17-19) We 
excluded patients younger than 18 years; patients who did not receive thrombolytic 
therapy; patients with stable and unstable angina, or NSTE-ACS; those who did not receive 
pre-hospital fibrinolysis; patients with conditions other than STEMI (e.g. stroke, pulmonary 
embolism); and referrals post-thrombolysis from other medical facilities to Victoria EC. 
Patients that lacked outcome information at discharge (e.g. survival, death or transferred) 
or a diagnostic ECG were also excluded from further analysis. 
Given that between two and five patients are thrombolysed per week, and the limitations 
with respect to local paper record keeping, we estimated that a sample size of between 100 
and 150 cases would be required. As the rate of thrombolysis was based on an estimation, 
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we decided to settle for a convenience sample without specifically powering the sample. As 
we did not plan inferential statistics that would be dependent on a specific sample size, we 
felt this would be appropriate.  
Initially, study participants were identified using Victoria EC’s resuscitation register. Specific 
data variables were then extracted from clinical records. The initial diagnostic ECGs and 90- 
minute post-thrombolysis ECGs were copied, anonymised and sent for interpretation. Three 
emergency medicine specialists, all with an enhanced emergency cardiology skillset, were 
involved as topic experts in the interpretation of the study ECGs. The ECGs were first analysed 
by Dr. Malan, one of the authors, followed by independent verification by another two 
specialist emergency medicine physicians who were not part of the research team. In 
instances of non-agreement on any of the ECG interpretations from any of the assessors, a 
final decision was made at a case conference involving all three assessors. Where assessors 
could still not agree on interpretation, the concerned ECG and corresponding case were 
excluded from the study. The interpretation and verification process is described in Figure 1. 
Other variables collected included age, gender, time of arrival/ triage, time of diagnostic ECG, 
time of thrombolysis, disposition from Victoria Hospital (i.e. discharge/ transfer) as well as 
outcome (i.e. survival or death). The latter relates to survival or death at Victoria Hospital 
following thrombolysis. We did not include disposition or outcome variables for patients that 
were transferred for PCI as the study protocol did not allow for data collection beyond 
Victoria Hospital. 
Data were summarised in a Microsoft Excel spread sheet (Microsoft Office, Redmond, USA). 
Descriptive statistics are provided using the mean and standard deviation (SD) and 
proportions are given throughout. We used the X2 and Fisher’s Exact test depending on 
sample size involved to test associations between the STEMI region affected and outcome 
(e.g. discharge from hospital, transfer or death). We also tested associations between the 
ECG resolution of STEMI at 90 minutes and outcome. A p-value of less than 0.05 was used to 
indicate significance. 
The study was approved by the Human Research Ethics Committee of the University of Cape 









Figure 1. Flowchart depicting evaluation of ECGs by topic experts 
 
Results 
Figure 2 describes the study subjects at each stage of the analysis. The ECG reviewers reached 
consensus in the first round of ECG interpretation for 83 of the cases and full consensus on 
the second round for the remainder of cases. Exclusions were mainly due to poor record 
keeping as well as records lacking the pre- and/or post thrombolysis ECG. Two patients with 
STEMI were excluded as thrombolysis was administered prior to attending Victoria hospital, 
and a further two patients were excluded due to an incorrect diagnosis of STEMI with 
subsequent thrombolysis. The latter two patients were both male patients aged 46 and 50 
years, respectively. Their ECGs revealed a Brugada configuration, a known pitfall in the 
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interpretation of ECGs for STEMI. For both patients, the error was later recognised and 
treatment was amended accordingly. Both patients survived although one required acute 




STEMI, ST-elevation myocardial infarct 
Figure 2. Participants to study at each stage of the analysis 
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Table 1 describes the gender, age and main outcomes of the study. Patients who died were 
older than those that survived but not significantly so (X2=0.3; p=0.87). 
 






Mean ± SD 
Inpatient 
stay (days) 




Mean ± SD 
Time from arrival 
to thrombolysis 
(min) 
Mean ± SD 
Total 87 64 (72) 56 ± 12 3 ± 2 30 ± 30 96 ±81 
Survive 56 (64) 40 (70) 56 ± 13 4 ± 1 27 ± 26 88 ± 64 
Transfer 26 (30) 22 (81) 55 ± 12 1 ± 0 34 ± 35 88 ± 58 
Died 5 (6) 2 (40) 61 ± 9 1 ± 0 10 ± 0 105 ± 106 
SD, standard deviation; STEMI, ST-elevation myocardial infarct; MI, myocardial infarct; ECG, 
electrocardiogram; min, minute; Survive, refers to patients discharged from Victoria Hospital 
following thrombolysis; Transfer, refers to patients transferred from Victoria Hospital 
following thrombolysis; Died, refers to patients that died at Victoria Hospital following 
thrombolysis 
 
Table 2 describes the suspected coronary regions affected (as per ECG interpretation), and 
the outcome matched to each of the affected areas. There was no difference between 
regions affected and patient outcome (p=0.31). Deaths were from just four of the 11 






Table 2. Suspected coronary regions affected by the STEMI (as per ECG) and the outcome 
matched to each affected area 
Suspected region affected n (%) Survived Transfer Died 
Any region 87 56 (64) 26 (30) 5 (6) 
Left Anterior Descending territory 31 (37) 18 10 3 
• Anterior Septal 10 (12) 7 (70) 2 (20) 1 (10) 
• Anterior lateral 1 (1.2) 1 (100) 0 0 
• Septal 1 (1.2) 1 (100) 0 0 
• Anterior 19 (23) 9 (47) 8 (42) 2 (11) 
Right Coronary Artery territory 43 (52) 31 10 2 
• Inferior 30 (36.1) 25 (83.3) 4 (13.3) 1 (3.3) 
• Inferior- Posterior 7 (8.4) 3 (43) 3 (43) 1 (14) 
• Inferior Right Ventricle  6 (7.2) 3 (50) 3 (50) 0 
Left Circumflex Artery territory 5 (6) 2 3 0 
• Inferior lateral 2 (2.4) 1 (50) 1 (50) 0 
• Lateral 2 (2.4) 0 2 (100) 0 
• High lateral 1 (1.2) 1 (100) 0 0 
Left main stem stenosis 4 (4.8) 2 (50) 2 (50) 0 
STEMI, ST-elevation myocardial infarct; ECG, electrocardiogram 
 
Of patients that survived, 84% (48/57) had resolution of their ST-segments. Of patients that 
were transferred, 88% (21/24) showed no resolution of their ST-segments. Resolution of ST-
segments was not seen for any patient that died. The difference between resolution of ST-





A notable finding of this study was that almost two-thirds of STEMI patients who presented 
to Victoria Hospital’s EC and received thrombolysis had subsequent resolution of ST-
segments and survived to discharge – none of which required rescue PCI. In contrast, just 
over a third of the thrombolysed patients had non-resolution of the ST-segment and either 
required transfer to a tertiary institution for rescue PCI or died at Victoria Hospital. Despite 
the limitations, this finding is significant. We already know from the literature that 
thrombolytic therapy is associated with an 80% resolution rate (compared to 90% for 
PCI).(17,18,20-25) However, our study findings suggest that the rate is substantially lower within 
our cohort. The study did not go into any detail regarding the various variables that may 
account for this. It does however suggest a greater reliance on rescue PCI than what would 
be expected judging from the existing literature. This is an important finding within a 
resource-limited environment if similar findings are made in replication of this study, as it 
may affect the way the local system is designed to respond to patients presenting with STEMI 
to centres without PCI capability (or even perhaps before patients reach these centres). The 
challenge is predicting the cohort that will show poor resolution. 
With regards to the STEMI region involved, the inferior region was most commonly affected, 
followed by the anterior region. This is a similar finding as to what Maharaj described back in 
2012, also within a Cape Town setting. (26) These two regions represented more than half of 
all STEMI patients included in our study. Moreover, anterior and inferior STEMI were 
disproportionately associated with a higher risk of transfer for rescue PCI and mortality. 
Naturally, the latter finding may simply be due to over-representation of the STEMIs found 
to affect these areas. What is interesting though is that mortality differed slightly from what 
has been described in the literature. Inferior STEMI tends to be associated with a better 
outcome and low in-hospital mortality (2%) which was not the case in our study. (17,18,20-24) 
Given the small mortality numbers, one should be careful to interpret this as significant. A 
larger sample is needed to review these findings as it may present a key to identifying 
potential patients that would benefit from earlier PCI within our resource-limited setting. 
There was little difference with existing literature in terms of the proportions of the various 
regions affected by STEMI. (17,18,20-24) It is worth noting that the longer delay in providing 
thrombolysis to patients that died, despite an earlier ECG diagnosis, was due to resuscitation 
requirements that were prioritised above thrombolysis in these patients. 
As a specific, rather than sensitive diagnostic tool, ECG interpretation can be a high-stakes 
decision depending on who interprets it. Two patients were wrongly diagnosed with STEMI 
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and subsequently thrombolysed. Although both cases were excluded, the inappropriate 
administration of thrombolysis (and the serious potential risks involved) highlights the 
importance of a skilled frontline workforce. As a new specialty, emergency physicians are not 
present locally in the same concentrations seen in more developed settings. (27) During the 
time of the study, there were only two emergency physicians employed by Victoria Hospital, 
which would suggest that there was no on-site specialist cover for most of the day. The Royal 
College of Emergency Medicine in the United Kingdom has specifically identified specialist 
sign off on all ECGs as a quality marker due to the recognition of the risks involved with 
error.(28) South Africa, and by extension the rest of Africa, have a long way to go to provide 
the same level of quality assurance within our ECs. The use of telemedicine, including various 
smartphone medical messaging applications, is seen as a potential bridge to the absence of 
on-site specialist cover. Specialist interpretation of ECGs would be an easy inclusion for such 
developments, however it needs to be built into a system that supports the findings. Seeing 
that the outcome appears to be worse within our setting, in terms of rescue PCI requirement 
and death, this could potentially hold much benefit for local patients. 
This study had a few limitations. As a retrospective, descriptive study it relied mostly on 
information recorded from the patient record. A large proportion of the sample had to be 
excluded due to poor record keeping, which, if available, may have affected the findings of 
this study. The numbers were therefore smaller than what was anticipated. We were unable 
to describe the time from onset of chest pain to presentation (or thrombolysis for that 
matter) as a direct result of poor record keeping. As such, we are unable to comment on 
whether any of the patients that suffered poor outcomes were due to a delay in presentation. 
A prospective study design will be required to improve the robustness of the dataset in future 
studies. The outcome (i.e. survival or death) of patients that were transferred was not 
described. This may not only have affected results, but also provided information about 
outcomes of patients sent for rescue PCI. Given the relatively large number of patients that 
required rescue PCI, this may warrant further study. The study did not record the specific 
agent used for thrombolysis. Although Streptokinase tends to be used for the majority of 
cases, Alteplase is used should contra-indications apply to Streptokinase. The difference in 
90-minute patency rates between the two agents (Streptokinase 60-68% versus Alteplase 73-
84%) may have affected resolution of the ST-segment post-thrombolysis. (17) This should be 
an important consideration for future study as better agents may hold a cost-benefit in the 
absence of access to PCI that may also benefit outcome. Caution should therefore be taken 
when comparing the findings of this study with studies where different agents, such as 
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Tenecteplase or Reteplase, were used. Given the study’s descriptive nature, none of the 
findings can assume direct relationships, but rather associations. Missing information is a 
huge challenge for any study conducted in a low- or middle-income setting. The improvement 
of quality care for patients with STEMI who present to the Victoria Hospital EC as well as the 
quality of the record keeping at the hospital constitute some of the opportunities highlighted 
by this study. 
 
Conclusions 
ST-elevation myocardial infarction is a serious complication of ischaemic heart disease. Up 
until recently, this has been less of a concern in sub-Saharan Africa but urbanisation and 
Westernised lifestyle changes have led to an increase in disease over the last few decades. 
Very little is known about the acute EC management of STEMI within this population, even 
in South Africa. This study described a higher than expected thrombolysis failure rate as well 
as a higher than expected association with inferior region STEMI for patients that attended 
an urban, South African, public hospital without PCI capability. The study produced a number 
of findings that will need unpacking in future research projects that may hold promise for 
service improvement. Replication of the study methods using prospective sampling, including 
outcome variables for patients referred for rescue PCI, thrombolysis agent and onset of 
symptoms, may provide insight into local STEMI pathways. The addition of variables related 
to the grade and experience of the ECG interpreter may also be of value. Finally, as with the 
Maharaj study, this study highlighted the need for improved health care records. It is ironic 
that the settings with the most to gain from clinical retrospective research are also the 
settings that are the least likely to consistently keep an adequate record to do so. The 
creation of a STEMI registry may address this, however, this will require funding that we 
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PURPOSE OF THE STUDY 
The purpose of this study is to describe ECG patterns and outcomes at discharge of 
thrombolysed ST-Elevation Myocardial Infarction (STEMI) patients at Victoria hospital (a 
facility without Primary Coronary Intervention capability) in Cape Town.  This study is being 
used to explore the creation of a larger registry to track short to medium term outcomes of 
thrombolysed STEMI patients who did not receive Primary Coronary Intervention within a 
low-to-middle-income setting. 
INTRODUCTION: 
STEMI is a serious complication of ischemic heart disease (IHD) and a major cause of death 
worldwide with an estimated annual incidence of seven million people. 1-2) In the United 
States of America (USA), approximately 500,000 episodes of Acute Myocardial Infarction 
(AMI) occur each year. Approximately 600 in every 100,000 men and 200 in every 100,000 
women have an AMI every year. The World Health Organization (WHO) estimates that 17.1 
million people died from ischemic heart disease (IHD) in 2004, representing 29% of all deaths 
globally. In the U.S., the overall mortality rates have been decreasing. The 30-day mortality 
rate among patients with AMI in 2010 ranged from 2.5% to 10%. Most of the studies were 
conducted in western countries and little is known about Africa. (1-2) 
Africa, and particularly sub-Saharan Africa, although initially characterized by a low 
prevalence of non- communicable disease, has seen in the last decades an increase in number 
of cardio-vascular events particularly coronary heart disease .The World Health Organization 
has predicted that Non- communicable diseases will exceed communicable diseases as the 
leading cause of death in Africa in 2030.3However, compared to other causes of heart 
disease, the burden of ischemic heart disease remains low in African descendants. The lack 
of surveillance data and registries as well as diagnostic and interventional capacities has 
made difficult the estimation of the magnitude of ischemic heart diseases in Africa.  
Post- apartheid South Africa with its emerging economy and urbanisation has seen an 
increase in mortality and morbidity associated with coronary heart disease and its 
complications such as AMI. (12-16) However, the true incidence of IHD is unknown due to lack 
of registry and epidemiologic data. The ACCESS study- South Africa conducted in 29 South 
African health facilities (in all provinces) from 2007-2008 was the 1st of its kind in the country 
to have established registries and documented the demographics and management 
strategies in patients admitted to hospital with a diagnosis of ACS. (12-16) 
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Acute Coronary Syndrome (ACS) is a huge problem worldwide and the standard of care is 
early diagnosis by ECG followed by treatment with Primary Coronary Intervention if STEMI is 
diagnosed.17ACS is also considered a problem locally. Although we have no good data to 
describe its incidence, anecdotal evidence suggests that hardly anyone presenting to a public 
hospital is likely to be treated with primary coronary intervention. The local standard of care 
is thrombolysis with ECG used to diagnose STEMI.  (18) 
ECG as a test for STEMI is very specific but not very sensitive meaning that is very good to 
make the diagnosis of myocardial infarction but not so good at ruling it out (98% specificity 
but only 20% sensitivity). (22) Therefore , some patients with STEMI could potentially be 
missed and some patients without STEMI could be diagnosed as such (referred to as a STEMI 
mimic).(22)  Treating a STEMI mimic with PCI has a relatively low risk of harm; in contrast, a 
STEMI mimic treated with thrombolysis – and its risk of causing haemorrhage – could 
potentially be fatal.(23-24) In addition, different STEMI regions carry different outcomes and 
responses to thrombolysis, suggesting that at least some patients will be better off with 
primary coronary intervention versus thrombolysis.(25)  The different STEMI regions and their 
ECG findings are summarized in Table 1. 
Table 1. STEMI regions, ECG findings and ST segment changes 
 
Location Leads ST segment 
Anterior wall MI V1 through V4 Elevation 
Lateral MI I, aVL, V5 and V6 Elevation 
Inferior Wall MI II, III and aVF Elevation 
Right Ventricular MI V4R Elevation 
Posterior wall MI V8 and V9  Elevation 






The aim of this study is to describe the outcomes at discharge from hospital of thrombolysed 
patients for STEMI and ECG changes associated with different coronary anatomical injury 
regions at a public hospital without Primary Coronary Intervention capability in Cape Town. 
OBJECTIVES 
• To describe outcome at discharge from hospital (survival, death or transferred) of 
patients thrombolysed for STEMI, and. 
• To describe the ECG findings associated with the different coronary injury regions 
represented in each STEMI case. 
• Sub-objectives 
- To describe outcome at discharge from hospital (survival, death or transferred) as 
per standard ECG coronary anatomical injury regions. 
- To describe timings (onset of chest pain, time of presentation and presentation time 
to thrombolysis time) surrounding thrombolysis in the Emergency Centre.  
- To evaluate ECG difference at 90 minutes following thrombolysis of each case. 
METHODOLOGY 
Study design 
It is a descriptive, retrospective study. 
Characteristics of the study population 
The study will be conducted at Victoria hospital, Cape Town.  Victoria hospital is a larger 
district hospital which provides medical and surgical services but has no percutaneous 
coronary intervention suite or cardiologist on site.   
Victoria hospital EC has 2 resuscitation beds, 8 cubicles in major (3 monitored beds) with a 
further 16 trolleys in the unit. The unit sees 132 patients per day with an average of 15 chest 
pain patients per day.  On average five patients are admitted daily to medicine as ACS and 
approximately four to five STEMIs are thrombolysed per week in the EC. 
Inclusion criteria  
All patients aged 18 years or older who presented with presumed STEMI (ECG) meeting 
AHA/ACC criteria for thrombolysis and who received thrombolysis in the EC at Victoria 
hospital during the study period: July 2014 to July 2015. 
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ECG criteria for acute STEMI in the absence of LVH and left bundle branch block (LBBB) have 
been defined by The European Society of Cardiology/ACCF/AHA/ World Federation task force 
and include the following (17-18) 
• ST elevation at J point of greater or equal to 2 mm (0.2 mv) in at least 2 contiguous leads 
in men or 1.5 mm (0.15 mv) in women in leads V2-V3 
• And/or greater or equal 1 mm (0.1 mv) in the other contiguous chest or limb leads. 
• Sgarbossa criteria are applied to a new or presumed new LBBB and a score of equal or 
more than 3 patients is considered for thrombolysis. (26) 
Exclusion criteria 
The following patients are excluded: patients younger than 18 years, patients who did not 
receive lytics, stable and unstable angina, Non-ST-Elevation Acute Coronary Syndromes 
(NSTE-ACS) (27) pre-hospital thrombolysis, thrombolysis for conditions other than MI (stroke, 
pulmonary embolism), thrombolysis from other medical facilities before referral to Victoria 
EC. 
Patients that lack outcome at discharge information (survival, death or transferred) or a 
diagnostic ECG will also be excluded from further analysis.  Patients with missing variables 
surrounding sub-objectives will not be excluded from analysis.  In these instances, 
calculations will be adapted to accommodate the missing values. 
Recruitment and Enrolment 
This study aims at collecting 100 eligible participants. The data collection will start using the 
period covering 1 July 2014 to 1 July 2015 and be extended if necessary.  Participants will be 
recruited by perusing Victoria hospital EC resuscitation register and additional relevant 
information will be extracted from patients’ clinical records (hospital folders). Entry criteria 
will be patients that have received thrombolysis in the emergency centre. Inclusion and 
exclusion criteria will be applied from there.  Anonymised copies of ECG scripts will be 
forwarded (see below under research procedures) to an independent panel for evaluation 
and agreement of STEMI anatomical classification. 
Research procedures and data collection methods 
Initially, study participants will be identified using Victoria Emergency Centre resuscitation 
register which is kept in the resuscitation bay of the Emergency Centre. A Microsoft Excel 
spread sheet will be used to capture relevant information from the resuscitation register and 
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clinical records of participants. Specific data variables will then be extracted from the records 
of identified patients as summarized below in Table 2. The initial diagnostic ECG and 90 - 
minute post- thrombolysis ECG will be copied from the folder for further analysis. Once all 
the data has been collected, folder numbers will be replaced with an individual study 
number. The ECGs will be anonymised similarly and labelled with the corresponding study 
number. 
The initial diagnostic ECG and 90-minute post- thrombolysis ECG will be copied from the 
folder for further analysis. Once all the data has been collected, folder numbers will be 
replaced with an individual study number. ECG will be anonymised similarly and labelled with 
the corresponding study number. 
Table 2 Variables to be collected 
 
Patient folder number 
Age 
Gender 
Time of arrival/ triage 
Time of diagnostic ECG 
Time of thrombolysis 
Disposal from hospital (discharge/ transfer) 
Hospital survival 
 
Three emergency medicine specialists, all with a particular interest in ECG interpretation, will 
be involved in the assessment of the study ECGs. Drs. Malan, Vallabh and Lahri are registered 
with the HPCSA and College of Emergency Physicians as specialist emergency physicians and 
jointly direct a two-day ECG workshop that is underwritten by the University of Cape Town 
(28). The ECG will firstly be analysed by Dr Malan, who is also study investigator and then 
independently verified by two specialists (emergency physicians) who are not part of the 
research team, Drs. Vallabh and Lahri. In instances of non-agreement (from one or more of 
the three assessors) then the ECG will be discussed in a meeting by all three assessors and a 
final result will be agreed upon.  In case of non-agreement at the meeting, concerned ECG 
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and corresponding case will be excluded from this part of the study. The outcome data for 







Figure 1 Flowchart depicting evaluation of ECGs by specialists 
 
Data safety and Monitoring 
The EC resuscitation register is kept in the resuscitation bay of the EC while clinical records are 
stored at the central admission department.  The electronic record is available to senior clinical 
persal staff.  The patients’ folder number will initially be used to link the register entries, the 
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clinical and electronic record.  Other identifiable information (name, addresses, etc.) will not be 
collected.  Participants will be allocated a unique study number after data collection has been 
completed.  This will occur prior to analysis.  Anonymised ECGs will be hand delivered by Dr 
Kibamba to each of the study specialists and he will collect the ECGs once again after assessments 
are completed.  All hardcopy copies of ECGs included in the study will be safely stored in a lockable 
cupboard in an access controlled office at Victoria Hospital.  Data captured electronically will be 
stored in a password protected folder on a work computer situated in the same access controlled 
office described above. 
Data analysis 
A statistician was consulted for the data analysis plan.  Descriptive statistics will be provided, using 
mean or median as a measure of central tendency and standard deviation or interquartile range 
as a measure of spread.  Proportions will be given throughout.  It is unlikely that the sample will 
provide a large enough power to perform detailed statistics on the intended subgroups and this 
will not be included.  This will be considered once the data proves useful and a larger registry is 
set up, once again in consultation with the statistician.  Confidence intervals will be quoted as a 
measure of precision.  Once data collection has been completed the statistician will again be 
consulted to reassess the data analysis plan and amendments will be made accordingly. 
ETHICAL CONSIDERATIONS 
Risks and benefits. 
Study investigators will not have direct contact with patients and only the clinical records and 
EC resuscitation register will be utilized.  This study is being used to explore the creation of a 
larger registry to track short to medium term outcomes of thrombolysed STEMI patients.  
Understanding the nuances surrounding outcome in a thrombolysed STEMI community 
within the local setting will be useful to guide policy and guidance both at the facilities 
providing thrombolysis and the tertiary referral centres with Primary Coronary Intervention 
capability in terms of referral protocols.  The main risks are exposing personal information. 
However, safeguard measures are in place to avoid that (see data safety above) 
Informed consent process 
Relevant study information will be obtained from EC registers and clinical records.  Following 
collection, data sets will be anonymised prior to analysis starting and a waiver of consent will 
be requested.   
Privacy and confidentiality 
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Efforts will be made to preserve privacy and confidentiality of participants through early 
anonymization.  Unique study numbers will be allocated to each participant prior to analysis 
starting.  
DISSEMINATION OF FINDINGS PLAN 
This project will serve as a pilot study for further investigations and establishment of larger 
registry to track short to medium term outcomes.  The findings of this study not only will be 
published in a form of original article or short report in an open access journal but also will 
be shared with Victoria hospital emergency centre management, the University of Cape 
Town as well as the Western Cape provincial government (DOH). 
PROJECT TIME LINE 
December 2015:  EMDRC proposal submission 
January 2016 – February 2016: UCT HREC Application 
February 2016 – April 2016: WCG Health Application 
April – May 2016:  Data collection 
May – June 2016:       Data Analysis 
June – Sep 2016:  Write up and submission for publication 
RESOURCES UTILISATION 
The study investigators will not conduct the study either data collection or analysis while on 
duty at the hospital.  However, the hospital data or admin clerk will be utilized for the 
retrieval of study participants’ clinical records (patients’ folders).  Writing- up, printing, and 
binding of copies of the project will be done without hospital resources. 
BUDGET 
It is important to note that there will not be external funding and the cost of this study will 
be borne by the investigator. 
Item                                                  Cost 
Personnel Compensation                     R 00.00 
Consulting services                                  R 0.00 
   Statistical services                                             
Travel                                                         R 00.00 
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  Transport and travel cost                                 
Equipment and furniture                      R 0.00 
  Computer  
Other                                                           R 2000.00 
   Telephone, cell phone, fax     R 250.00 
   Printing, copying & binding    R 1500.00 
   Internet & email                       R 250.00 
Ethics committee fee                          R 0.00 
Total cost                                          R 2000.00 
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